Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

NCT00349180 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2009-03-27

No results posted yet for this study

Summary

This study is performed to confirm the optimal dose for THR (total hip replacement).

Conditions

  • Arthroplasty, Replacement, Hip

Interventions

DRUG

Enoxaparin sodium

Sponsors & Collaborators

Principal Investigators

  • Yoshihiro IKEDA · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00349180 on ClinicalTrials.gov